Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prostatype Genomics ABOSTO:PROGEN +2.56%23 Debt-to-Equity is 0.20 as of Dec. 2025, which is at its 10-year median of 0.20. GuruFocus rates OSTO:PROGEN with a GF Score™ of 23/100 and a GF Value™ of kr0.04 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Prostatype Genomics AB ranks better than 56.83% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Prostatype Genomics AB's Debt-to-Equity or its related term are showing as below:
OSTO:PROGEN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.2 Max: 1.54
Current: 0.2
During the past 7 years, the highest Debt-to-Equity Ratio of Prostatype Genomics AB was 1.54. The lowest was 0.00. And the median was 0.20.
OSTO:PROGEN's Debt-to-Equity is ranked better than 56.83% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.32
vs OSTO:PROGEN: 0.20
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Prostatype Genomics AB Debt-to-Equity Related Terms
Prostatype Genomics AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Prostatype Genomics AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:PROGEN vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB (OSTO:PROGEN) has a Debt-to-Equity of 0.20 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Prostatype Genomics AB and its competitors. This is near median its historical median of 0.20. According to the industry distribution chart, Prostatype Genomics AB ranks #79 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 43.2%.
Is Prostatype Genomics AB's Debt-to-Equity too high?
Prostatype Genomics AB's current Debt-to-Equity of 0.20 is near median its 10-year median of 0.20. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.32. Prostatype Genomics AB's value of 0.20 is 37.5% below this industry median. Based on the distribution chart, Prostatype Genomics AB ranks #79 out of 183 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Prostatype Genomics AB has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #79 out of 183 companies for Debt-to-Equity. This puts Prostatype Genomics AB in the upper half of its industry. The industry median Debt-to-Equity is 0.32. Prostatype Genomics AB's value of 0.20 is 37.5% below this benchmark. While the company's 10-year median is 0.20 vs. the industry median of 0.32, Prostatype Genomics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.32, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prostatype Genomics AB's current Debt-to-Equity of 0.20 is 37.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Prostatype Genomics AB and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current Debt-to-Equity is 0.20, which is near median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.04, compared to a current price of kr0.16 — trading 300% above its estimated fair value. The current Debt-to-Equity is 0.20, which is near median its 10-year median of 0.20 and 37.5% below the Medical Diagnostics & Research industry median of 0.32. Prostatype Genomics AB's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Debt-to-Equity is 0.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.16 is trading 300% above its estimated GF Value™ of kr0.04.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
Debt-to-Equity: 0.20 (near median its 10-year median of 0.20)
GF Value™: kr0.04 vs. price of kr0.16 (300% above fair value)
Industry Position: 37.5% below the Medical Diagnostics & Research median (#79 of 183)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score
Get the complete analysis for OSTO:PROGEN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
